Download Files:
Zolunicant
$1,160 – $9,420
Products Details
Product Description
– Zolunicant (MM-110) is a potent inhibitor against nicotinic α3β4 receptors with an IC50 of 0.90 μM to combat addiction. Zolunicant can decrease the self-administration of several addictive agents including morphine, methamphetamine, nicotine, and ethanol in rat model. Zolunicant can be studied as a potential research for multiple forms of agent abuse[1]. Zolunicant also reveals a potent leishmanicide effect against Leishmania amazonensis[2].
Web ID
– HY-147428
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– COVID-19-immunoregulation
Molecular Formula
– C22H28N2O3
References
– [1]Pace CJ, et al. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. European journal of pharmacology. 2004;492(2-3):159-67.|[2]Delorenzi JC, et al. In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis. Antimicrob Agents Chemother. 2002;46(7):2111-5.|[3]Glick SD, et al. 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats. European journal of pharmacology. 2006;537(1-3):94-8.
CAS Number
– 188125-42-0
Molecular Weight
– 368.47
Compound Purity
– 99.29
SMILES
– COC([C@]12[C@@]3([H])[N@@](CCC4=C2NC5=CC=CC=C54)C[C@@](C[C@@H]3CCOC)([H])C1)=O
Clinical Information
– No Development Reported
Research Area
– Infection; Neurological Disease
Solubility
– 10 mM in DMSO
Target
– nAChR;Parasite
Isoform
– Leishmania
Pathway
– Anti-infection;Membrane Transporter/Ion Channel;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
